|Mr. Khoso Baluch||Chief Exec. Officer and Director||208.32k||N/A||59|
|Mr. Robert W. Cook||Chief Financial Officer||N/A||N/A||61|
|Mr. John L. Armstrong Jr., MBA||Head of HR and Exec. VP of Technical Operations||N/A||N/A||73|
|Dr. Judith R. Abrams M.D., FRCPC||Chief Medical Officer||N/A||N/A||57|
|Mr. John Ortiz||VP of Regulatory Affairs and Quality Assurance||N/A||N/A||N/A|
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Bridgewater, New Jersey.
CorMedix, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 6. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 1; Compensation: 10.